Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Jonathan Vignes

Critical Care Medicine Lafayette, LA Medical Doctor

NPI 1992187090 CMS profile 3897770

155 Hospital Dr., Ste 101, Lafayette, LA 70503

Open in the dashboard

General payments

$8,561

284 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Vignes of Lafayette, LA is reported in the CMS Open Payments database as having received $8,561 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,184 124
2024 General $1,465 65
2023 General $1,364 69
2022 General $547 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Vignes
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Jonathan Vignes were reported at $5,184. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Jonathan Vignes Critical Care Medicine median Middle half National median
2019 $0 $149 $51–$535 $163
2020 $0 $110 $30–$325 $114
2021 $0 $125 $34–$403 $132
2022 $547 $157 $49–$582 $149
2023 $1,364 $162 $56–$621 $160
2024 $1,465 $168 $53–$634 $164
2025 $5,184 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Intuitive Surgical, Inc. $2,776 4 payments
  2. GlaxoSmithKline, LLC. $1,382 86 payments
  3. AstraZeneca Pharmaceuticals LP $1,072 48 payments
  4. Genzyme Corporation $792 29 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $416 18 payments
  6. Mallinckrodt Hospital Products Inc. $311 12 payments
  7. Merck Sharp & Dohme Corporation $240 12 payments
  8. Insmed, Inc. $234 15 payments
  9. Regeneron Healthcare Solutions, Inc. $207 7 payments
  10. Grifols USA, LLC $199 8 payments
  11. Other $932 45 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $5,909 281 payments
  2. Education $2,500 1 payment
  3. Travel and Lodging $152 2 payments
Products named General payments · program years 2022–2025
  1. Da Vinci Surgical System $2,776 4 payments
  2. TRELEGY ELLIPTA $810 47 payments
  3. DUPIXENT $792 29 payments
  4. NUCALA $572 39 payments
  5. FASENRA $486 20 payments
  6. ACTHAR $311 12 payments
  7. TEZSPIRE $252 11 payments
  8. Arikayce $234 15 payments
  9. BREZTRI $231 10 payments
  10. Prolastin-C Liquid $199 8 payments
  11. Other $1,977 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

537

Median for Pulmonary Disease: 936

Drug cost

$430,653

Median for Pulmonary Disease: $487,987

Branded share of claims

76.7%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 13 $168,793
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 150 $115,359
Fasenra Pen Benralizumab Brand 12 $74,387
Breo Ellipta Fluticasone/Vilanterol Brand 67 $32,317
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 33 $19,268
Wixela Inhub Fluticasone Propion/Salmeterol Brand 16 $6,134
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 21 $4,797
Symbicort Budesonide/Formoterol Fumarate Brand 14 $3,304
Albuterol Sulfate Hfa Albuterol Sulfate Brand 62 $2,874
Ventolin Hfa Albuterol Sulfate Brand 24 $2,300

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$84,148

Medicare's payments for the services billed

Medicare patients

422

Average age 74

Services billed

868

227 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 54%
Ischemic heart disease 50%
Arthritis 49%
Heart failure 39%
Diabetes 36%
Chronic kidney disease 36%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $260
  • Regeneron Healthcare Solutions, Inc. $26
$287 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $190
$190 12 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $164
$164 150 —
NUCALA
  • GlaxoSmithKline, LLC. $129
$129 — —
TEZSPIRE
  • Amgen Inc. $78
  • AstraZeneca Pharmaceuticals LP $27
$105 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record